Pfizer Inc. (PFE)

FairStock Score: 62/100 — STEADY

Key Financials

Strengths

• Strong free cash flow generation of $13.4B provides financial flexibility and defensive characteristics
• Diversified portfolio across vaccines, internal medicine, and oncology reduces single-product dependency
• Low beta of 0.41 indicates relative stability in healthcare defensive positioning
• Established brand portfolio with Prevnar, Eliquis providing recurring revenue streams

Concerns

• Q4 2025 showed $1.6B net loss with -9.39% margin indicating severe operational deterioration
• Piotroski F-Score of 3/9 signals poor financial quality across multiple metrics
• EV/EBITDA of 287.38 is absurdly high, suggesting massive overvaluation or earnings crisis
• ROE of 8.89% and ROCE of 5.68% demonstrate capital destruction below cost of capital

AI Analysis

Pfizer presents a deeply troubling investment picture that demands caution. While the company operates in a defensive, essential healthcare sector with recognizable brands like Eliquis and Prevnar, the financial deterioration is unmistakable. A $1.6 billion net loss in the latest quarter with a negative 9.39% margin suggests serious operational challenges—likely stemming from the post-pandemic cliff in COVID-19 vaccine and treatment revenues. The Piotroski F-Score of merely 3/9 indicates weak financial health across multiple dimensions, and the Altman Z-Score of 1.71 places the company in the "grey zone" approaching financial distress. Most alarming is the astronomical EV/EBITDA ratio of 287.38, which is indefensible for a mature pharmaceutical company. Yes, Pfizer generates $13.4 billion in free cash flow and maintains a low beta of 0.41, suggesting some stability. However, with ROE of only 8.89% and ROCE of 5.68%, the company is destroying shareholder value—these returns fall well below capital costs. The dividend yield being unavailable combined with negative earnings signals potential dividend pressure ahead. At 19.83 P/E on negative earnings guidance, the market is pricing in recovery that remains highly uncertain. Graham would demand a substantial margin of safety here, which simply doesn't exist. This is a business in transition, burdened by patent expirations and revenue cliff dynamics, trading at prices that offer no protection for the downside risks ahead.

Bull Case

Pfizer's $13.4B annual free cash flow provides substantial downside protection and could support dividend restoration. A successful turnaround in pipeline productivity and patent cliff management could drive valuation re-rating, particularly if key drug launches gain traction and operating margins normalize toward historical 20%+ levels.

Bear Case

The company faces a structural revenue cliff from expiring patents with insufficient pipeline success to offset declines. Continued quarterly losses, dividend pressure, and potential covenant violations could force asset sales or restructuring, destroying shareholder value in a multi-year turnaround scenario.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer